Oxigene Inc says drug meets main goal of ovarian cancer trial

[riky]

Oxigene Inc says drug meets main goal of ovarian cancer trial

(Reuters) - Oxigene Inc said on Tuesday that its experimental drug Zybrestat combined with Roche's big selling cancer drug Avastin significantly slowed progression of recurrent ovarian cancer better than Avastin alone in a midstage clinical trial. Shares of tiny Oxigene, which had been halted prior to announcement of the trial results, more than doubled in extended trading. The drugs, which use different mechanisms to deprive tumors of blood supply and oxygen needed to grow, met the primary goal of the study by demonstrating a statistically significant increase in progression-free survival (PFS), or the time it takes before the cancer begins to worsen. "This promising combination warrants further evaluation particularly given the significant need for new treatment options in relapsed ovarian cancer," Dr. Bradley Monk, lead investigator of the study, said in a statement.

Source: You are not allowed to view links. Register or Login